Economic And Health Burden Characterization of Migraine Population At The FUSAT Hospital - PD61 - An Opportunity For Innovative Tailored Intervention

Sep 29, 2026

Uploaded by Levi

Economic and social impacts of migraine are quantified in the FUSAT hospital setting in Chile using retrospective clinical and claims data from 2018 to 2023. Migraine patients were identified and analyzed across outpatient visits, emergency care, hospitalizations, and sick leave, with costs standardized to 2023 values and comorbidities assessed. Migraine affects 2.8% of the FUSAT population, with higher annual expenditures and increased sick-leave costs versus non-migraine patients. Results support tailored interventions and a proposed performance-based risk-sharing model for preventive rimegepant management.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages1

Reading Time3 min

AccessFree to download

Introduction

Methods

Results

Conclusions

PD60 Leveraging Real-World Evidence For Rare Disease And Oncology Health Technology Assessments: Insights From Pulse Infoframe Inc.’s Hybrid Approach Daniel Lewi ([Dlewi@pulseinfoframe.com](Dlewi@pulseinfoframe.com)) and Femida Gwadry-Sridhar Introduction: Health technology assessment (HTA) of rare diseases and cancer face significant challenges in illustrating value. This is compounded by small patient populations, limited data, and undefined endpoints. We tackled these barriers by engaging patients directly, defining a pragmatic data strategy, combining site-based and decentralized models focusing on patient-first data collection, and incorporating patient preferences to generate high quality real-world evidence (RWE) to inform HTA decisions. Methods: A relevant use case supporting pricing reimbursement forauveal melanoma treatment required ambispective data that illustrated an unmet need. Integrated data, including patient-reported outcomes and clinical registries can help shape better therapeutic practices and inform regulatory approval pathways. This can then support data capture and inform patient-centric endpoints for regulatory approval, aligning clinical trials with real-world needs. Results: The data collected in a RWE platform and used in conjunction with early access program data resulted in pricing reimbursement in multiple regions. Substantiating unmet need requires robust, long-term data collected in a standardized data format in the Pulse registry platform to demonstrate disease progression in untreated patients. A similar strategy was used in lung cancer to support apricing dossier and subsequent approval. The design of studies relevant for HTA requires a data driven approach with relevant and pragmatic study design that focuses on expected patient benefits. These examples were conducted on historical cohorts but should include contemporaneous data and patient input through preferences and outcomes in future analyses. Conclusions: The road to accessing therapies is not a straight line. Our work demonstrated how RWE bridged gaps between clinical trials and real-world applications. By aligning patient needs with regulatory priorities, RWE facilitates informed, patient-centered decisions, improving access to lifesaving therapies for patients with rare diseases or cancer worldwide. PD61 Economic And Health Burden Characterization of Migraine Population At The FUSAT Hospital: An Opportunity For Innovative Tailored Intervention Ruben Rojas, Luis Arriagada, Gabriel Pinto, Carolina Cruz, Patricia Fernandez, Vicente Garzaro, Tomás Abbott ([tomaseduardo.abbott@pfizer.com](tomaseduardo.abbott@pfizer.com)) and Monica Velasquez Introduction: Migraine is a neurological condition with significant impacts on quality of life, productivity, and healthcare costs. In Chile, understanding the economic and health burden of migraine in a closed health center, such as the FUSAT hospital, is essential to generate evidence of the burden associated with the pathology and to define effective strategies for its management. Methods: This retrospective study used clinical and claims data collected at the FUSAT Hospital between 2018 and 2023 . Patients with diagnosis of migraine were identified and information from outpatient consultations, emergency care, hospitalizations, and sick leave were analyzed. Costs were adjusted to 2023 values and comorbidities were evaluated Results: Migraine diagnosis was found in 2.8 percent (n=395) of the FUSAT population, predominantly in women aged 45 to75 years. Hypertension (30.1%), anxiety (28.6%), and depression (12%) were frequent among migraine patients. Regarding healthcare costs, the annual expenditure for a patient with migraine was 25 percent higher than the costs reported for patients without migraine. Concerning sick leaves, 12 percent of the migraine population reported at least one sick leave, with an expected cost per patient of CLP2,854,700 (USD2,854), which represents a 2

FAQs

What data sources and study period were used to characterize migraine burden at FUSAT?

The study used clinical and claims data collected at the FUSAT Hospital between 2018 and 2023, analyzing outpatient consultations, emergency care, hospitalizations, and sick leave.

How common was migraine in the FUSAT population and which demographics were most affected?

Migraine accounted for 2.8% of the FUSAT population (n=395), predominantly in women aged 45 to 75 years.

What were the key findings on healthcare costs and sick leave for migraine patients?

Annual expenditure for a migraine patient was 25% higher than for patients without migraine. For sick leave, 12% reported at least one sick leave with an expected cost per patient of CLP 2,854,700 (USD 2,854), a 20% increase versus the average FUSAT patient.

Sep 29, 2026

Uploaded by Levi